Memorial Sloan-Kettering Cancer Center;Generon (Shanghai) Corporation, Ltd.
发明人:
Van Den Brink, Marcel,Hanash, Alan,Lindemans, Caroline,Tang, Tom
申请号：
AU2020227014
公开号：
AU2020227014A1
申请日:
2020.09.01
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020227014A120200917.pdf#####ABSTRACT The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.
